Skip to content
MARKETS / NYSE / BLCO
NYSE · OPHTHALMIC GOODS · LARGE CAP

Bausch & Lomb Corp. BLCO

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.1B
▲ 6.5% YoY
$-360.0M
$-66.0M
In brief

What this company does

Bausch + Lomb offers a portfolio of approximately 400 products, including contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products. As of December 31, 2025, the company had approximately 13,000 employees, which included approximately 7,000 in production, 4,200 in sales and marketing, 900 in general and administrative positions and 900 in R&D. McKesson Corporation and Cardinal Health, Inc. each accounted for 10% or more of the company's total revenues for 2025 and 2024. Its portfolio of products falls into three operating and reportable segments: Vision Care, Pharmaceuticals and Surgical.

Written from the business description in Bausch & Lomb Corp's annual report to the U.S. Securities and Exchange Commission, filed 18 February 2026. Every sentence was checked against that document before publication.

Growth
USD 5.1B
Revenue, FY2025 · full 6-year series below
Revenue $B Net income $B
FY2025 · Revenue 5.1 · Net income -0.4
2B4B202020212022202320242025
Compound annual growth
+10.6%
+8.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−7 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 2.2% · Net -6.9%
5%-2%-4%-6%202020212022202320242025
ROE
FY2025 · ROE -5.6%
0.5%1.0%1.5%-2.0%-4.0%202020212022202320242025

Each USD of equity lost 6 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -66.0
250.0M500.0M-80.0M-160.0M202020212022202320242025

Total assetsUSD 14.0B
EquityUSD 6.4B
CashUSD 383.0M
Gross debtUSD 5.0B
Net debtUSD 4.7B
Current ratio1.55×

Net debt stands at 72% of equity.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 202520242023202220212020
Revenue $B5.14.84.13.83.83.4
Operating income $B0.10.20.10.20.30.3
EBITDA $B0.30.30.30.30.50.4
Income tax $B0.00.10.10.10.10.3
Net income $B−0.4−0.3−0.30.00.2−0.0
Free cash flow $B−0.1−0.1−0.20.20.70.3
EPS, diluted $−1.02−0.90−0.740.020.52−0.05
Dividend / sh $······
Payout %······
ROE %−5.6−4.8−3.70.12.0·
Shares out B0.350.350.350.350.35·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 22 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 54 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOphthalmic Goods
Listed onNYSE
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2020

Share this section

Download image